NCT07312409 Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?
| NCT ID | NCT07312409 |
| Status | Recruiting |
| Phase | — |
| Sponsor | York University |
| Condition | Long COVID Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-06-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-weeks of taurine supplementation (self-administered), on vascular function and the cardio/cerebrovascular responses to upright posture. We will measure resting vascular function with an EndoPAT device, resting heart rate variability, and the blood pressure, heart rate, and brain blood flow responses to 5 minutes of head-up tilt before and after weeks of taurine supplementation in LC. We hypothesize that the 12 weeks of supplementation will improve both resting vascular function and the responses to upright tilt. In turn, we hypothesize that symptoms will also improve (as measured by questionnaires).
Eligibility Criteria
Inclusion Criteria: * Participants will have had symptoms of Long COVID post-infection for at least 3 months Exclusion Criteria: * Inability to undergo tilt table testing for 5 minutes * Inability to transport selves to York University from their homes * Inability to speak English, or provide a translator * Blood clotting disorders
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07312409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Long COVID Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07312409 currently recruiting?
Yes, NCT07312409 is actively recruiting participants. Contact the research team at edgell@yorku.ca for enrollment information.
Where is the NCT07312409 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07312409 clinical trial?
NCT07312409 is sponsored by York University. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.